Latest News - Novaliq

Monday, May 08, 2017 | Partnerships, Novaliq

Novaliq Conducts a First-in-Class Ocular Neuropathic Pain and Anti-Inflammatory Cannabinoid Drug Development Program in Collaboration with the University of Cologne

Novaliq announced successful application of a first-in-class ocular neuropathic pain and anti-inflammatory cannabinoid-based dry eye disease (DED) treatment approach in collaboration with the Universi…

Read the full story

Monday, March 20, 2017 | Dry Eye, Pharmaceutical, Novaliq

Novaliq Announces Licensing Agreement With AFT Pharmaceuticals for Distribution of NovaTears

Novaliq announced a strategic licensing agreement with AFT Pharmaceuticals for the commercialization of Novaliq's lead product NovaTears in Australia and New Zealand. NovaTears is Novaliq&rsquo…

Read the full story

Thursday, January 05, 2017 | Clinical Trials, Novaliq

Novaliq Announces Positive Topline Results of Phase 2 Clinical Trial Evaluating CyclASol in Adults with Moderate to Severe Dry Eye Disease

Novaliq announced positive phase 2 results evaluating CyclASol, a clear, preservative-free cyclosporine A solution, in 207 patients with moderate to severe dry eye disease (DED). CyclASol showed a con…

Read the full story

Thursday, October 06, 2016 | Management/Leadership, Novaliq

Novaliq Strengthens Executive Management Team by Appointing Christian Roesky, PhD, as Chief Executive Officer

Novaliq GmbH announced the appointment of Christian Roesky, PhD, as the company’s chief executive officer, effective November 1, 2016. Dr. Roesky will lead Novaliq as it develops and brings to m…

Read the full story

Thursday, September 08, 2016 | Management/Leadership, Novaliq

Novaliq Names Renown International Experts to Inaugural Scientific Advisory Board

Novaliq announced the appointment of several renown experts to its newly formed scientific advisory board (SAB). The newly appointed SAB will strategically advise and support Novaliq as it continues t…

Read the full story

Thursday, May 05, 2016 | Clinical Trials, Dry Eye, Novaliq

Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol for Treatment of Moderate to Severe Dry Eye Disease

Novaliq announced the completion of enrollment in its phase 2 clinical trial that is evaluating the safety, efficacy, and tolerability of CyclASol for the treatment of moderate to severe dry eye disea…

Read the full story

Tuesday, February 16, 2016 | Clinical Trials, Dry Eye, Novaliq

Novaliq Begins Phase 2 Clinical Trial of CyclASol for the Treatment of Moderate to Severe Dry Eye Disease

Novaliq announced that it has begun enrolling patients in a phase 2 clinical trial that will evaluate the safety, efficacy, and tolerability of CyclASol for the treatment of moderate to severe dry eye…

Read the full story

Wednesday, December 16, 2015 | Clinical Trials, Novaliq

Novaliq: NovaTears Stabilizes the Tear Film and Receives Dry Eye Symptoms in Patients with Evaporative Dry Eye Disease

NovaTears was found to significantly improve four of five measures associated with evaporative DED, new research shows, according to a company news release. NovaTears was also shown to be safe a…

Read the full story

Tuesday, December 08, 2015 | Management/Leadership, Novaliq

Novaliq Appoints Friedrich Von Bohlen, PhD, as Chairman, and Gerald Cagle, PhD, as New Member of Supervisory Board

Novaliq announced that Friedrich von Bohlen, PhD, has been appointed chairman of the company’s supervisory board and that Jerry Cagle, PhD, has joined the board as member, according to a company…

Read the full story

Thursday, October 01, 2015 | Partnerships, Novaliq

Ursapharm and Novaliq Announce European Partnership Agreement

Ursapharm and Novaliq jointly announced its partnership agreement as well as the initial European launch of EvoTearsä, according to a company news release. As part of the agreement, Ursapharm obt…

Read the full story

Thursday, September 10, 2015 | Management/Leadership, Novaliq

Novaliq Strengthens Executive Management Team by Appointing Oliver Schluter, PhD, as Managing Director and CFO, and Hartmut Voss, PhD, as CBO

Novaliq announced that Oliver Schlüter, PhD, has joined the company as managing director and chief financial officer, and that Hartmut Voss, PhD, has been named chief business officer, according …

Read the full story